CA2997376C - Methods of treating neurodegenerative disorders in a particular patient population - Google Patents

Methods of treating neurodegenerative disorders in a particular patient population Download PDF

Info

Publication number
CA2997376C
CA2997376C CA2997376A CA2997376A CA2997376C CA 2997376 C CA2997376 C CA 2997376C CA 2997376 A CA2997376 A CA 2997376A CA 2997376 A CA2997376 A CA 2997376A CA 2997376 C CA2997376 C CA 2997376C
Authority
CA
Canada
Prior art keywords
pharmaceutical composition
subject
apoe4
mmse
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2997376A
Other languages
English (en)
French (fr)
Other versions
CA2997376A1 (en
Inventor
Susan ABUSHAKRA
Aidan POWER
Martin TOLAR
John Hey
Jeremy Yu
Petr Kocis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alzheon Inc
Original Assignee
Alzheon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58240195&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2997376(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alzheon Inc filed Critical Alzheon Inc
Publication of CA2997376A1 publication Critical patent/CA2997376A1/en
Application granted granted Critical
Publication of CA2997376C publication Critical patent/CA2997376C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2997376A 2015-09-10 2016-09-09 Methods of treating neurodegenerative disorders in a particular patient population Active CA2997376C (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201562216404P 2015-09-10 2015-09-10
US62/216,404 2015-09-10
US201662290287P 2016-02-02 2016-02-02
US62/290,287 2016-02-02
US201662302027P 2016-03-01 2016-03-01
US62/302,027 2016-03-01
US201662365809P 2016-07-22 2016-07-22
US62/365,809 2016-07-22
PCT/US2016/051091 WO2017044840A1 (en) 2015-09-10 2016-09-09 Methods of treating neurodegenerative disorders in a particular patient population

Publications (2)

Publication Number Publication Date
CA2997376A1 CA2997376A1 (en) 2017-03-16
CA2997376C true CA2997376C (en) 2024-05-14

Family

ID=58240195

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2997376A Active CA2997376C (en) 2015-09-10 2016-09-09 Methods of treating neurodegenerative disorders in a particular patient population

Country Status (21)

Country Link
US (3) US11191742B2 (https=)
EP (2) EP4275750B1 (https=)
JP (4) JP6789579B2 (https=)
KR (2) KR102547164B1 (https=)
CN (3) CN108289870A (https=)
AU (1) AU2016319107B2 (https=)
CA (1) CA2997376C (https=)
DK (1) DK3347002T3 (https=)
ES (1) ES2952727T3 (https=)
FI (1) FI3347002T3 (https=)
HR (1) HRP20230809T1 (https=)
HU (1) HUE062511T2 (https=)
LT (1) LT3347002T (https=)
MD (1) MD3347002T2 (https=)
MX (2) MX392677B (https=)
PL (1) PL3347002T3 (https=)
PT (1) PT3347002T (https=)
RS (1) RS64481B1 (https=)
SI (1) SI3347002T1 (https=)
SM (1) SMT202300250T1 (https=)
WO (1) WO2017044840A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102645633B1 (ko) 2014-03-21 2024-03-11 알제온, 인크. 신경학적 장애를 치료하는 방법
EP4275750B1 (en) * 2015-09-10 2026-05-06 Alzheon, Inc. Treatment of alzheimer's disease in a particular patient population
CN114805211B (zh) 2017-03-21 2024-08-23 润佳（苏州）医药科技有限公司 同位素富集3-氨基-1-丙磺酸衍生物、药物组合物及其用途
CN110003058B (zh) 2018-01-04 2022-01-25 润佳（苏州）医药科技有限公司 3-((l-缬氨酰基)氨基)-3,3-二氘-1-丙磺酸晶型、制备方法及用途
SI3829568T1 (sl) * 2018-08-01 2024-02-29 Alzheon, Inc. Derivati sulfopropanojske kisline za zdravljenje nevrodegenerativnih motenj
HUE070101T2 (hu) * 2018-08-01 2025-05-28 Alzheon Inc 3-Szulfopropánsav neurodegeneratív rendellenességek kezelésére
CN111170901A (zh) * 2018-11-13 2020-05-19 润佳（苏州）医药科技有限公司 3-((l-缬氨酰基)氨基)-1-丙磺酸晶型、制备方法及其用途
UA129160C2 (uk) * 2019-06-17 2025-01-29 Алзхеон, Інк. Спосіб лікування хвороби альцгеймера
CN116059192B (zh) 2019-11-13 2024-10-29 润佳（苏州）医药科技有限公司 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途
JP2024542844A (ja) * 2021-12-09 2024-11-15 アルツェオン・インコーポレーテッド アルツハイマー病の処置に使用されるａｌｚ－８０１
WO2023150381A1 (en) * 2022-02-07 2023-08-10 Alzheon, Inc. Alz-801 for use in treating a covid-19 associated neurological symptom

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
JP3265577B2 (ja) 1992-10-13 2002-03-11 デューク・ユニバーシティ アポリポ蛋白ｅの４型イソ型の測定法
US20050031651A1 (en) 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
US20050142191A1 (en) 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
US20060079578A1 (en) 2003-06-23 2006-04-13 Julie Laurin Pharmaceutical formulations of amyloid inhibiting compounds
US20070010573A1 (en) 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
SG145784A1 (en) 2003-08-11 2008-09-29 California Inst Of Techn Microfluidic large scale integration
CA2611586A1 (en) 2005-04-12 2007-06-21 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
DK2089417T3 (en) * 2006-10-12 2015-03-23 Bhi Ltd Partnership Methods, Compounds, Compositions and Vehicles for Delivery of 3-Amion-1-Propanesulfonic Acid
KR101450356B1 (ko) 2006-11-24 2014-10-15 에이씨 이뮨 에스.에이. 알츠하이머와 같은 아밀로이드 또는 아밀로이드-유사 단백질과 관련된 질환의 치료를 위한 ｎ-(메틸)-1ｈ-피라졸-3-아민, ｎ-(메틸)-피리딘-2-아민 및 ｎ-(메틸)-티아졸-2-아민 유도체
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2322163A1 (en) * 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
US20120009125A1 (en) 2010-07-06 2012-01-12 Lombard Jay L Apoe4 and apoj biomarker-based prevention and treatment of dementia
ES2705027T3 (es) * 2010-08-19 2019-03-21 Buck Institute For Age Res Métodos de tratamiento del deterioro cognitivo leve (DCL) y trastornos relacionados
EP2847218A4 (en) * 2012-05-08 2015-12-30 Univ Ramot APOE4 ANTIBODY FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
HUE044737T2 (hu) * 2013-05-06 2019-11-28 Baxalta Inc Alzheimer-kór szubpopulációk kezelése egyesített immunglubulin G-vel
CA2938466C (en) * 2014-02-08 2021-11-02 Genentech, Inc. Methods of treating alzheimer's disease
KR102645633B1 (ko) 2014-03-21 2024-03-11 알제온, 인크. 신경학적 장애를 치료하는 방법
EP4275750B1 (en) * 2015-09-10 2026-05-06 Alzheon, Inc. Treatment of alzheimer's disease in a particular patient population

Also Published As

Publication number Publication date
EP4275750B1 (en) 2026-05-06
JP2025065545A (ja) 2025-04-17
HUE062511T2 (hu) 2023-11-28
PL3347002T3 (pl) 2023-11-13
MX392677B (es) 2025-03-24
EP4275750A2 (en) 2023-11-15
CA2997376A1 (en) 2017-03-16
US20230414541A1 (en) 2023-12-28
WO2017044840A1 (en) 2017-03-16
EP3347002A4 (en) 2019-04-24
FI3347002T3 (fi) 2023-08-10
JP2022145949A (ja) 2022-10-04
AU2016319107A1 (en) 2018-03-22
RS64481B1 (sr) 2023-09-29
MD3347002T2 (ro) 2023-10-31
AU2016319107B2 (en) 2021-02-25
SMT202300250T1 (it) 2023-09-06
KR20180051561A (ko) 2018-05-16
KR20220042480A (ko) 2022-04-05
KR102547164B1 (ko) 2023-06-22
HRP20230809T1 (hr) 2023-10-27
CN116712422A (zh) 2023-09-08
EP3347002A1 (en) 2018-07-18
DK3347002T3 (da) 2023-08-14
LT3347002T (lt) 2023-09-11
JP6789579B2 (ja) 2020-11-25
PT3347002T (pt) 2023-07-27
MX2022003128A (es) 2022-08-02
JP2020200352A (ja) 2020-12-17
HK1257874A1 (en) 2019-11-01
MX2018003023A (es) 2018-06-06
US20220096406A1 (en) 2022-03-31
CN108289870A (zh) 2018-07-17
KR102412997B1 (ko) 2022-06-23
EP3347002B1 (en) 2023-06-07
JP2018526407A (ja) 2018-09-13
EP4275750A3 (en) 2024-01-17
ES2952727T3 (es) 2023-11-03
US11191742B2 (en) 2021-12-07
CN116712423A (zh) 2023-09-08
SI3347002T1 (sl) 2023-12-29
JP7128536B2 (ja) 2022-08-31

Similar Documents

Publication Publication Date Title
US20230414541A1 (en) Methods of treating neurodegenerative disorders in a particular population
ES2698927T3 (es) Terapia para trastornos neurológicos basada en baclofeno y acamprosato
EP2680836B1 (en) New compositions for treating neurological disorders
CN109890391B (zh) 痴呆症的治疗
EP3962488A1 (en) A method of treating mental, behavioral, cognitive disorders
US20180250249A1 (en) Methods of treating neurodegenerative disorders in a particular population
HK40094581A (en) Treatment of alzheimer's disease in a particular patient population
HK1257874B (en) Treatment of alzheimer's disease in a particular patient population
US12042493B2 (en) Pharmaceutical compounds for use in treating Huntington's disease
US10736876B2 (en) Idalopirdine-based combinatorial therapies of Alzheimer's disease
US20210236445A1 (en) Baclofen and acamprosate based therapy of alzheimer's disease in patients having lost responsiveness to acetylcholinesterase inhibitor therapy

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210907

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240909

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240909

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240909

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250901

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250901